Latest News and Events
Filter by
Selections
April 26, 2022
Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia
Read MoreApril 25, 2022
Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market
Read MoreApril 6, 2022
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Read MoreMarch 24, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases
Read MoreMarch 15, 2022
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma
Read MoreFebruary 24, 2022